Evidence map›Paper›PMID 41502514›Full record

ArticleOncology research2025

Biological Features of KLC2 Mutations in Chronic Myeloid Leukemia and Their Contribution to Inducing Drug Resistance.

Rabindranath Bera, Yotaro Ochi, Ying-Jung Huang, Ming-Chung Kuo, Kenichi Yoshida, Seishi Ogawa, Lee-Yung Shih

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncology research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Rabindranath BeraDivision of Hematology-Oncology, Chang Gung Memorial Hospital-Linkou, Taoyuan City, 333, Taiwan.
Yotaro OchiDepartment of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, 6068501, Japan.
Ying-Jung HuangDivision of Hematology-Oncology, Chang Gung Memorial Hospital-Linkou, Taoyuan City, 333, Taiwan.
Ming-Chung KuoDivision of Hematology-Oncology, Chang Gung Memorial Hospital-Linkou, Taoyuan City, 333, Taiwan.
Kenichi YoshidaDivision of Cancer Evolution, National Cancer Center Research Institute, Tokyo, 1040045, Japan.
Seishi OgawaDepartment of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, 6068501, Japan.
Lee-Yung ShihDivision of Hematology-Oncology, Chang Gung Memorial Hospital-Linkou, Taoyuan City, 333, Taiwan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Breakpoint Cluster Region-Abelson (BCR::ABL1) fusion protein is essential in the pathogenesis of chronic myeloid leukemia (CML); however, the chronic-to-blast phase transformation remains elusive. We identified novel kinesin light chain 2 ( Methods: To evaluate the biological role of KLC2 mutants (MT) in CML cells, we expressed Results: Conclusions: This study demonstrates the biological and functional importance of KLC2 mutation in CML cells, potentially enabling the development of better treatment strategies for CML patients carrying

Indexed as

Drug Resistance, NeoplasmLeukemia, Myelogenous, Chronic, BCR-ABL PositiveMicrotubule-Associated ProteinsMutationAnimalsApoptosisCell Line, TumorCell ProliferationFusion Proteins, bcr-ablHumansImatinib MesylateK562 CellsKinesinsMiceProtein Kinase InhibitorsSTAT3 Transcription FactorFusion Proteins, bcr-ablImatinib MesylateKinesinsKlc2 protein, mouseMicrotubule-Associated ProteinsProtein Kinase InhibitorsSTAT3 protein, humanSTAT3 Transcription FactorChronic myeloid leukemia (CML)drug resistancekinesin light chain 2 (KLC2)myeloid blast transformationsignal transducer and activator of transcription 3 (STAT3)

Identifiers

PMID41502514
PMCPMC12774541

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.